We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Vive la révolution!
- Historical RA treatment
- Modern RA treatment
- “Future” RA treatment
- Biomarkers
- Biomarkers of drug-free remission (DFR)
- Clinical predictors of DFR in RA
- DFR: induced or predestined?
- Balance of immune tolerance in DFR
- RA as imbalanced immunity
- Difficulties in studying DFR
- Drug withdrawal as an experimental model
- Pro-inflammatory biomarkers of DFR
- Pro-inflammatory biomarkers in drug withdrawal studies
- RETRO study
- Autoantibodies and drug tapering
- Cellular biomarkers of flare (BioRRA study)
- BioRRA: memory lymphocyte subsets increase at flare onset
- BioRRA scRNAseq
- Changes in lymphocytes trigger RA flare
- Tolerogenic biomarkers of DFR
- BioRRA: CD4+ Tregs in DFR
- BIO-FLARE: CD4+ Tregs in DFR
- CD4+ Tregs in bDMARD tapering
- Treg functional assays in drug tapering
- Biomarkers in personalised RA therapy
- Longitudinal biomarker monitoring
- Three-step biomarker score for tapering
- Translation to clinical practice
- Summary
- Acknowledgements
- Financial disclosures
Topics Covered
- Rheumatoid arthritis (RA) treatments
- Drug-Free Remission (DFR)
- Pro-inflammatory biomarkers of DFR
- Tolerogenic biomarkers of DFR
- Immune tolerance
- RETRO study
- BioRRA study
Links
Series:
- The Immune System - Key Concepts and Questions
- Periodic Reports: Advances in Clinical Interventions and Research Platforms
Categories:
Therapeutic Areas:
Talk Citation
Baker, K.F. (2026, January 28). Drug-free remission in rheumatoid arthritis: wishful thinking or achievable goal? [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved January 28, 2026, from https://doi.org/10.69645/XOVX3874.Export Citation (RIS)
Publication History
- Published on January 28, 2026
Financial Disclosures
- Kenneth F. Baker is named as an inventor on a patent application by Newcastle University (“Prediction of Drug-Free Remission in Rheumatoid Arthritis”; International Patent Application Number PCT/GB2019/050902), and has received funding/research support from Pfizer, Genentech and Alamar Biosciences, and consultancy fees from Modern Biosciences, unrelated to the work included in this presentation.
Other Talks in the Series: The Immune System - Key Concepts and Questions
Other Talks in the Series: Periodic Reports: Advances in Clinical Interventions and Research Platforms
Transcript
Please wait while the transcript is being prepared...
0:00
Hello. My name is Ken Baker.
I'm an NIHR advanced fellow
and honorary consultant
rheumatologist
here in Newcastle upon Tyne
in the United Kingdom,
and I'm delighted to
talk to you today about
Drug-Free Remission in
Rheumatoid Arthritis:
Wishful Thinking or
Achievable Goal?
This here is
photographic evidence
that although I'm a
clinically trained doctor,
I do have a PhD, and
they occasionally let me
go into the lab to do
some sciencey stuff.
0:27
Rheumatoid arthritis
has undergone
a treatment revolution
over the past two decades.
We've gone from a situation
where joint damage and
disability were commonplace
and almost unavoidable for patients
with rheumatoid arthritis,
to one in the modern
era, where we can
now effectively switch off
joint inflammation for
the majority of patients to
achieve remission
with no joint damage.
How have we achieved this?
Well, this has been through
the effective use of
modern disease-modifying
anti-rheumatic drugs,
or DMARDs for short.
1:00
Historically, rheumatoid arthritis
used to be treated like this.
Painkillers were started
as a first-line treatment,
and when joint damage happened,
a DMARD was added in,
and when further joint
damage happened,
the dose of the DMARD
was slowly increased,
and maybe that was switched
to a second DMARD.
Unfortunately, this start
low and go slow approach
resulted in prolonged
joint inflammation
and joint damage in the
majority of patients.
1:28
If we contrast that with
modern rheumatoid
arthritis treatment,
we now start DMARDs'
first presentation,
and if there's an
ongoing active disease,
second DMARDs are added in
in combination therapy,
and we now have an upper tier of
biologic treatments
now available for use.
This is very much maximising
the early window
opportunity and also
using combination DMARD
therapies as well.
The result for most patients,
then, is maintenance of
remission and prevention
of joint damage,
with remission now
being achievable in
at least 60% of
patients in our clinic.